Table 47. Patient characteristics–perphenazine versus risperidone

| **Author, Year** | **Study Characteristics** | **Inclusion and Exclusion Criteria** | **Population** | **Interventions** |
| --- | --- | --- | --- | --- |
| **Ascher-Svanum et al. 2008**131 | ***Study design:*** RCT  ***Registration #:*** NR  ***Study population:*** Schizophrenia  ***DSM Classification:*** DSM IV  ***Study period:*** May–98 to Sep–02  ***Number of centers:*** Multicenter(n = 21)  ***Setting:*** Mixed  ***Country:*** USA  ***Financial support:*** Multiple sources (NR)  ***Washout period performed:*** NA  ***Run-in phase performed:*** no  ***Followup period:*** 12 mo | ***Main inclusion criteria:*** aged >18 years; DSM–IV criteria for Sz, schizoaffective or schizophreniform disorders based on the SCID; minimum score of 18 on BPRS  ***Main exclusion criteria:*** serious or unstable physical illnesses; high risk of suicide; lactating or pregnant women and individuals with medical conditions contraindicating use of any study medication | ***G1:***  ***Age (mean±SD):*** 44.20±11.90  ***Males (n(%)):*** 28/48 (58.3%)  ***Ethnicity:*** Caucasian 27/48(52.3%)  ***BL symptom scores:*** BPRS (mean±SD): 28.9±31.90  PANSS (mean±SD): 81.0±18.9  ***G2:***  ***Age (mean±SD):*** 42.00±11.80  ***Males (n(%)):*** 130/217 (60.0%)  ***Ethnicity:*** Caucasian 118/217 (54.3%)  ***BL symptom scores:*** BPRS (mean±SD):  32.4±12.20  PANSS (mean±SD): 87.40±20.70 | ***G1:***  ***Classification:*** FGA  ***Drug:*** Perphenazine  ***Dosage:*** NR  ***Intervals:*** NR  ***G2:***  ***Classification:*** SGA  ***Drug:*** Olanzapine  ***Dosage:*** NR  ***Intervals:*** NR |

**Table 47. Patient characteristics–perphenazine versus risperidone (continued)**

| **Author, Year** | **Study Characteristics** | **Inclusion and Exclusion Criteria** | **Population** | **Interventions** |
| --- | --- | --- | --- | --- |
| **Lieberman et al. 2005**23 | ***Study design:*** RCT  ***Registration #:*** NR  ***Study population:*** Schizophrenia  ***DSM Classification:*** DSM IV  ***Study period:*** Jan–01 to Dec–04  ***Number of centers:*** Multicenter(n = 57)  ***Setting:*** Outpatient  ***Country:*** USA  ***Financial support:*** Multiple sources (AstraZeneca, Bristol–Myers Squibb, Forest, Janssen, Eli Lilly, Otsuka, Pfizer, Zenith Goldline, Schering–Plough, and Novartis)  ***Washout period performed:*** NA  ***Run-in phase performed:*** no  ***Followup period:*** 18 mo | ***Main inclusion criteria:*** Age 18–65 yrs; Dx of Sz; able to take oral AP medication  ***Main exclusion criteria:*** Schizoaffective disorder, mental retardation, other cognitive disorders; Hx of serious adverse reactions to study drugs; had only one schizophrenic episode; Hx of treatment resistance; pregnant or breast feeding; other serious and unstable medical condition. | ***G1:***  ***Age (mean±SD):*** 40.00±11.10  ***Males (n(%)):*** 199/261 (76.3%)  ***Ethnicity:*** Caucasian 152/261 (58.2%)  ***BL symptom scores:*** PANSS (mean±SD): 74.3±18.1  ***G2:***  ***Age (mean±SD):*** 40.80±10.80  ***Males (n(%)):*** 244/336 (72.6%)  ***Ethnicity:*** Caucasian 196/336 (58.3%)  ***BL symptom scores:*** PANSS (mean±SD):  76.1±18.2  ***G3:***  ***Age (mean±SD):*** 40.90±11.20  ***Males (n(%)):*** 255/337 (75.7%)  ***Ethnicity:*** Caucasian 213/337 (63.2%)  ***BL symptom scores:*** PANSS (mean±SD): 75.7±16.9  ***G4:***  ***Age (mean±SD):*** 40.60±11.30  ***Males (n(%)):*** 253/341 (74.2%)  ***Ethnicity:*** Caucasian 204/301 (59.8%)  ***BL symptom scores:*** PANSS (mean±SD): 76.4±16.6  ***G5:***  ***Age (mean±SD):*** 40.10±11.00  ***Males (n(%)):*** 129/185 (69.7%)  ***Ethnicity:*** Caucasian 109/185 (58.9%)  ***BL symptom scores:*** PANSS (mean±SD): 75.4±18.6 | ***G1:***  ***Classification:*** FGA  ***Drug:*** Perphenazine  ***Dosage:*** 8–32mg/d  ***Intervals:*** once daily  ***G2:***  ***Classification:*** SGA  ***Drug:*** Olanzapine  ***Dosage:*** 7.5–30mg/d  ***Intervals:*** once daily  ***G3:***  ***Classification:*** SGA  ***Drug:*** Quetiapine  ***Dosage:*** 200–800mg/d  ***Intervals:*** BID  ***G4:***  ***Classification:*** SGA  ***Drug:*** Risperidone  ***Dosage:*** 1.5–6.0mg/d  ***Intervals:*** once daily  ***G5:***  ***Classification:*** SGA  ***Drug:*** Ziprasidone  ***Dosage:*** 40–160mg/d  ***Intervals:*** BID |

AP = antipsychotic; BID  = Twice daily; BL = baseline; BPRS = Brief Psychiatric Rating Scale; CGI = Clinical Global Impressions; d = day; DSM = Diagnostic and Statistical Manual of Mental Disorders; DX = diagnosis; FGA = first-generation antipsychotic; Hx = history; mg = milligram; n = number; NA = not applicable; NR = not reported; PANSS  = Positive and Negative Syndrome Scale; RCT = randomized controlled trial; SD = standard deviation; SGA = second-generation antipsychotic; Sz = schizophrenia; wk = week; yr = year